NCT06972472进行中（未招募）3 期
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 600
- 试验地点
- 157
- 主要终点
- Change from Baseline in Hemoglobin A1c (HbA1c)
研究概览
简要总结
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792).
Participation in the study will last about 18 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have body mass index (BMI) ≥25 kilograms per square meter (kg/m2) at screening
- •Have type 2 diabetes
- •Have hemoglobin A1c (HbA1c) ≥7% and ≤10% at screening
- •Have a history of at least one unsuccessful dietary effort to lose body weight
排除标准
- •Have type 1 diabetes
- •Have an unstable body weight within 90 days prior to screening
- •Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening
- •Have acute or chronic hepatitis or pancreatitis
- •Are taking other medications or alternative remedies to manage weight loss
研究组 & 干预措施
Orforglipron Dose 1
Experimental
Participants will receive orforglipron orally
干预措施: Orforglipron (Drug)
Orforglipron Dose 2
Experimental
Participants will receive orforglipron orally
干预措施: Orforglipron (Drug)
Orforglipron Dose 3
Experimental
Participants will receive orforglipron orally
干预措施: Orforglipron (Drug)
Orforglipron Dose 4
Experimental
Participants will receive orforglipron orally
干预措施: Orforglipron (Drug)
Placebo
Placebo Comparator
Participants will receive placebo orally
干预措施: Placebo (Drug)
结局指标
主要结局
Change from Baseline in Hemoglobin A1c (HbA1c)
时间窗: Baseline, Week 40
次要结局
- Change from Baseline in Body Mass Index (BMI)(Baseline, Week 72)
- Percent Change from Baseline in Body Weight(Baseline up to 72 weeks)
- Change from Baseline in HbA1c at Week 72(Baseline, Week 72)
- Change from Baseline in Fasting Glucose(Baseline up to 72 weeks)
- Percentage of Participants Achieving HbA1c of <7.0%(Baseline up to 72 weeks)
- Percentage of Participants Achieving Weight Reduction of ≥5%(Baseline up to 72 weeks)
- Change from Baseline in Waist Circumference(Baseline up to 72 weeks)
- Change from Baseline in Body Max Index (BMI)(Baseline, Week 72)
- Change from Baseline in Systolic Blood Pressure (SBP)(Baseline up to 72 weeks)
- Percent Change from Baseline in Triglycerides(Baseline up to 72 weeks)
- Change from Baseline in EQ-5D-5L(Baseline, Week 72)
- Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC-ss) of Orforglipron(Predose through Week 48)
研究者
研究点 (157)
Loading locations...
相似试验
进行中（未招募）
1 期
A Study in Patients with Obesity and Obstructive Sleep ApneaEUCTR2021-004551-16-CZEli Lilly and Company206
尚未招募
3 期
A Study of LY3437943 in Obese or Overweight PatientsCTRI/2023/11/059873Eli Lilly and Company India Pvt Ltd
招募中
3 期
A Study of LY3437943 in Participants with Type 2 Diabetes Mellitus who have Obesity or OverweightCTRI/2023/10/058324Eli Lilly and Company India Pvt Ltd
进行中（未招募）
1 期
A Study in Patients with Obesity and Obstructive Sleep ApneaEUCTR2021-004552-41-CZEli Lilly and Company206
进行中（未招募）
3 期
The purpose of this study is to evaluate the effect and safety of tirzepatide in participants with obstructive sleep apnea and obesity who are and plan to stay on PAP therapy in GPI-2JPRN-jRCT2031220155Masaki Takeshi206